RecruitingPhase 3NCT06119581
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Sponsor: Eli Lilly and Company
Austin, TX · Fort Bliss, TX · Houston, TX · +84 more sites